Skip to main content

Table 1 List of MDM2-p53 inhibitors in completed clinical trials

From: Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Drug Disease Combination with Action Phase Status Trial nr Sponzor Time
RG7112 (RO5045337) Advanced solid tumors    I Completed NCT00559533* Hoffmann-LaRoche 2007–2012
  Hematologic neoplasm    I Completed NCT00623870* Hoffmann-La Roche 2008–2012
  Solid tumors    I Completed NCT01164033* Hoffmann-La Roche 2010–2013
  Sarcoma Doxorubicin DNA damage Ib Completed NCT01605526* Hoffmann-La Roche 2012–2013
  Acute myelogenous leukemia (AML) Cytarabine DNA damage Ib Completed NCT01635296* Hoffmann-La Roche 2012–2013
  Extension study of studies marked with*    I Completed NCT01677780 Hoffmann-La Roche 2012–2017
Idasanutlin (RG7388) Advanced malignancies, except leukemia    I Completed NCT01462175 Hoffmann-La Roche 2011–2014
  Solid tumors    I Completed NCT03362723 Hoffmann-La Roche 2017–2019
  Acute myelogenous leukemia Idarubicin
Daunorubicin
Cytarabine
DNA damage
DNA damage
DNA damage
I/Ib Completed NCT01773408 Hoffmann-La Roche 2013–2016
  Relapsed and refractory AML Cytarabine DNA damage III Terminated NCT02545283 Hoffmann-La Roche 2012–2020
  Non-Hodgkin’s lymphoma Obinutuzumab
Rituximab
Anti-CD20
Anti-CD20
I/Ib Terminated NCT02624986 Hoffmann-La Roche 2015–2019
  Relapsed and refractory AML Venetoclax BCL-2 inhibitor Ib Completed NCT02670044 Hoffmann-La Roche 2016–2020
  Relapsed and refractory follicular lymphoma, relapsed and refractory diffuse large B-cell lymphoma Obinutuzumab
Venetoclax
Rituximab
Anti-CD20
BCL-2 inhibitor
Anti-CD20
Ib/II Terminated NCT03135262 Hoffmann-La Roche 2018–2020
  Acute myelogenous leukemia Cytarabine
Daunorubicin
DNA damage
DNA damage
Ib/II Completed NCT03850535 Hoffmann-La Roche 2019–2020
AMG-232 (KRT-232) Advanced solid tumors, multiple myeloma    I Completed NCT01723020 Amgen 2012–2017
  Acute myelogenous leukemia Trametinib MEK inhibitor I Completed NCT02016729 Kartos Therapeutics, Inc. 2014–2017
  Metastatic melanoma Trametinib
Dabrafenib
MEK inhibitor
BRAF inhibitor
Ib/IIa Completed NCT02110355 Kartos Therapeutics, Inc. 2014–2018
APG-115
(AA-115)
Advanced solid tumors. Lymphomas    I Completed NCT02935907 Ascentage Pharma Group, Inc. 2016–2019
CGM097 Advanced solid tumors with TP53wt    I Completed NCT01760525 Novartis Pharmaceuticals 2013–2019
HDM201 Liposarcoma Ribociclib CDKinhibitor Ib/II Completed NCT02343172 Novartis Pharmaceuticals 2015–2019
DS-3032b (Milademetan) Advanced solid tumors, lymphomas    I Completed NCT01877382 Daiichi Sankyo Co., Ltd. 2013–2020
  Relapsed and refractory AML    I Completed NCT03671564 Daiichi Sankyo Co., Ltd. 2018–2019
  Acute myelogenous leukemia Quizartinib Tyrosine kinase inhibitor I Terminated NCT03552029 Daiichi Sankyo Co., Ltd. 2018–2021
  Acute myelogenous leukemia, myelodysplastic syndromes 5-Azacitidine DNA damage I Terminated NCT02319369 Daiichi Sankyo Co., Ltd. 2014–2021
ALRN-6924 Advanced solid tumors, lymphomas    I/IIa Completed NCT02264613 Aileron Therapeutics 2014–2020
  Acute myelogenous leukemia, myelodysplastic syndromes Cytarabine DNA damage I/Ib Completed NCT02909972 Aileron Therapeutics 2016–2019
JNJ-26854165 Advanced of refractory solid tumors     Completed NCT00676910 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2006–2010
SAR405838 Solid tumors Pimasertib MEK inhibitor I Completed NCT01985191 Sanofi 2013–2016
  1. *These studies were extended by clinical trial NCT01677780